explore -WSS

explore

author：knowledge 2025-09-29 22:36:36 - browse：4698

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： New lesbian bars spark hope amid disappearing LGBTQ+ spaces

focus

WSS

Male and female sex labels in research insufficient, scientists say

Synthetic human embryos? Researchers say term is overblown

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Why do we get seasonal allergies?

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Thousands protest in Iraq for a second day over burning of Quran in Sweden

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Here's how to stay safe from wildfire smoke amid reduced air quality

Novavax promises a turnaround & Lilly roils the obesity market

Eating disorder hotline's move to chatbot carried cost for volunteers

Peter Hotez and the public health issue of online harassment

Readout Newsletter: CAR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Change Healthcare outage fallout shows need for new oversight

Peter Hotez and the public health issue of online harassment

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

focus

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

The simple reason for the increase in autism diagnosis

Boston's new lab space is opening empty

Male and female sex labels in research insufficient, scientists say

Eating disorder hotline's move to chatbot carried cost for volunteers

Thousands protest in Iraq for a second day over burning of Quran in Sweden

leisure time

Wikipedia

focus

explore